Cimadamore A.; Cheng L.; Scarpelli M.; Lopez-Beltran A.; Mollica V.; Montironi R.; Massari F., Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation, «EUROPEAN UROLOGY», 2021, 79, pp. 17 - 19 [Scientific article]
Santoni M.; Massari F.; Santoni G.; Cimadamore A.; Montironi R.; Battelli N., Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy, «EUROPEAN UROLOGY», 2021, 79, pp. 887 - 889 [Scientific article]
Rizzo A.; Mollica V.; Massari F., Re: Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021;384:1125-35, «EUROPEAN UROLOGY ONCOLOGY», 2021, 4, pp. 670 - 670 [Scientific article]
Mollica V.; Rizzo A.; Massari F., Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2: The Conflict of Adding Immunotherapy to Chemotherapy in Metastatic Urothelial Carcinoma: A Matter of the Right Timing?, «EUROPEAN UROLOGY ONCOLOGY», 2021, 4, pp. 854 - 854 [Scientific article]
Franceschini, Tania; Giunchi, Francesca; Mollica, Veronica; Altimari, Annalisa; Capizzi, Elisa; Banfi, Mattia; Schiavina, Riccardo; Fiorentino, Michelangelo; Massari, Francesco, Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study, «DIAGNOSTICS», 2021, 11, Article number: 184 , pp. 1 - 6 [Scientific article]Open Access
Rizzo A.; Merler S.; Sorgentoni G.; Oderda M.; Mollica V.; Gadaleta-Caldarola G.; Santoni M.; Massari F., Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2021, 17, pp. 1237 - 1243 [Scientific article]
Rizzo A.; Mollica V.; Santoni M.; Massari F., Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 1225 - 1232 [Scientific article]
Basso U.; Procopio G.; Fornarini G.; Massari F.; Bearz A.; Fratino L.; Milella M.; Bassanelli M.; Ermacora P.; Bimbatti D.; Verzoni E.; Rizzo M.; Porta C., Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16), «ONCOLOGY», 2021, 99, pp. 747 - 755 [Scientific article]
Rizzo A.; Mollica V.; Cimadamore A.; Santoni M.; Scarpelli M.; Schiavina R.; Cheng L.; Lopez-Beltran A.; Brunocilla E.; Montironi R.; Massari F., TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review, «TRANSLATIONAL ANDROLOGY AND UROLOGY», 2021, 10, pp. 1541 - 1552 [Scientific article]Open Access
Marchetti A.; Rosellini M.; Mollica V.; Rizzo A.; Tassinari E.; Nuvola G.; Cimadamore A.; Santoni M.; Fiorentino M.; Montironi R.; Massari F., The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory?, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2021, 22, Article number: 6237 , pp. 6237 - 6237 [Scientific article]Open Access
Cimadamore A.; Cheng L.; Scarpelli M.; Massari F.; Mollica V.; Santoni M.; Lopez-Beltran A.; Montironi R.; Moch H., Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review, «TRANSLATIONAL ANDROLOGY AND UROLOGY», 2021, 10, pp. 1506 - 1520 [Scientific article]Open Access
Rosellini M.; Santoni M.; Mollica V.; Rizzo A.; Cimadamore A.; Scarpelli M.; Storti N.; Battelli N.; Montironi R.; Massari F., Treating prostate cancer by antibody-drug conjugates, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2021, 22, Article number: 1551 , pp. 1 - 15 [Scientific article]Open Access
Mollica V.; Brocchi S.; Dall'olio F.G.; Marcolin L.; Paccapelo A.; Santoni M.; Rizzo A.; Montironi R.; Golfieri R.; Massari F.; Ardizzoni A., Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough, «CANCERS», 2021, 13, Article number: 3492 , pp. 1 - 10 [Scientific article]Open Access
Mollica V.; Di Nunno V.; Santoni M.; Cimadamore A.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Mariani C.; Battelli N.; Montironi R.; Massari F., An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer, «EXPERT REVIEW OF MOLECULAR DIAGNOSTICS», 2020, 20, pp. 207 - 217 [Scientific article]
Aurilio G.; Cimadamore A.; Mazzucchelli R.; Lopez-Beltran A.; Verri E.; Scarpelli M.; Massari F.; Cheng L.; Santoni M.; Montironi R., Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications, «CELLS», 2020, 9, Article number: 2653 , pp. 1 - 14 [Scientific article]Open Access
